Products for Research Use Only
RegisterLogin

Daclatasvir-d6

CAT: 0804-HY-10466S-01Size: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10466S-01Size:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Daclatasvir-d6 is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively[1][2][3].
CAS Number
1801709-41-0
Product Name Alternative
BMS-790052-d6; EBP 883-d6
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
HCV; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Others
Applications
COVID-19-anti-virus
Field of Research
Infection
Purity
99.64
Solubility
10 mM in DMSO
Smiles
[2H]C([2H])([2H])OC(N[C@@H](C(C)C)C(N1[C@H](C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=C([C@H]6N(CCC6)C([C@H](C(C)C)NC(OC([2H])([2H])[2H])=O)=O)N5)C=C4)C=C3)N2)CCC1)=O)=O
Molecular Formula
C40H44D6N8O6
Molecular Weight
744.91
Precautions
H315, H319, H335
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765.|[3]Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465 (7294) :96-100.|[4]Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8 (1) :12469.|[5]Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58 (8) :4555-64.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-10466S1Daclatasvir-13C2, d6
HY-10466-01Daclatasvir
HY-10466S2-01Daclatasvir-d16
HY-10465-01Daclatasvir (dihydrochloride)
HY-10466RDaclatasvir (Standard)
HY-133247-01Daclatasvir Impurity B
HY-133248Daclatasvir Impurity C
HY-10465R-01Daclatasvir (dihydrochloride) (Standard)
HY-133246-01Monodes (N-carboxymethyl) valine Daclatasvir
HY-110225-01Levetiracetam-d6 (ring-d6)

Alternative Products

CatalogName
CS-O-11958Daclatasvir-d6
CS-O-11957Daclatasvir-13C2, d6
445728-01Daclatasvir SRRS Isomer-d6
TRC-D101512-100MGDaclatasvir RSSR Isomer-d6
457931-01N-Acetyl Daclatasvir-d6
TRC-D101532-100MGDaclatasvir RRRR Isomer-d6
BA1854-5Daclatasvir

Popular Products